Selective elimination of erosive cells

Patent metadata

Field	Value
Publication number	US-9512228-B2
Application number	US-201214124876-A
Country	US
Kind code	B2
Filing date	Jun 18, 2012
Priority date	Jun 17, 2011
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

First claim

The invention claimed is:

1. A method for treating cartilage destruction or bone erosion in a subject having osteoarthritis: comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof, to said subject, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody.

2. The method of claim 1 , wherein said anti-NKG2A antibody stimulates selective elimination of cartilage destructive cells or reduces formation of bone eroding cells.

3. The method of claim 2 , wherein the cartilage destructive cells are fibroblast-like synoviocytes (FLS).

4. The method of claim 2 , wherein the bone eroding cells are osteoclasts.

5. A method for treating osteoarthritis, comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof, to a subject in need thereof, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody.

6. The method of claim 1 , wherein the anti-NKG2A antibody is a humanized or human antibody.

7. The method of claim 6 , wherein the anti-NKG2A antibody is humZ270 having a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3.

8. The method of claim 1 , wherein the heavy chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 2 and the light chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 3.

9. The method of claim 1 , wherein said anti-NKG2A antibody or an antigen binding fragment thereof, competes with an antibody comprising a heavy chain comprising the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 2 and the light chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 3.

10. The method of claim 5 , wherein the anti-NKG2A antibody is a humanized or human antibody.

11. The method of claim 10 , wherein the anti-NKG2A antibody is humZ270 having a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3.

12. The method of claim 5 , wherein the heavy chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 2 and the light chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 3.

13. The method of claim 5 , wherein said anti-NKG2A antibody or an antigen binding fragment thereof, competes with an antibody comprising a heavy chain comprising the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 2 and the light chain of said anti-NKG2A antibody comprises the CDR1, CDR2, and CDR3 of the heavy chain having the amino acid sequence of SEQ ID NO: 3.

14. The method of claim 1 , wherein said antibody is selected from the group consisting of an antibody comprising an IgG4 Fc domain and an antibody comprising a mutated Fe domain, wherein said mutation(s) results in reduced Fcγ receptor binding functions.

15. The method of claim 14 , wherein said antibody comprises a mutated Fc domain, wherein said mutation(s) results in reduced Fcγ receptor binding functions.

16. The method of claim 5 , wherein said antibody is selected from the group consisting of an antibody comprising an IgG4 Fc domain, and an antibody comprising a mutated Fc domain, wherein said mutation(s) results in reduced Fcγ receptor binding functions.

17. The method of claim 16 , wherein said antibody comprises a mutated Fe domain, wherein said mutation(s) results in reduced Fcγ receptor binding functions.

18. The method of claim 1 , wherein said antibody competes with the antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3 for binding to NKG2A.

19. The method of claim 5 , wherein said antibody competes with the antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3 for binding to NKG2A.

Assignees

• Soederstroem Kalle
• Galsgaard Elisabeth Douglas
• Novo Nordisk As

Inventors

• Soederstroem Kalle
• Galsgaard Elisabeth Douglas

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P19/10

  for osteoporosis · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title